Combined Targeting of EGFR and BRAF Triggers Regression of Osimertinib Resistance by Using Osimertinib and Vemurafenib Concurrently in a Patient with Heterogeneity Between Different Lesions.
Thoracic cancer（2021）
Key words
acquired BRAF mutation,EGFR mutation,heterogeneity,osimertinib,vemurafenib
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined